Leaflet for drug Tryparsamide. Made by Pharmaceutical Specialties [May & Baker] Ltd., Dagenham, England, circa 1925, by arrangement with the Rockefeller Institute for Medical Research. Kept in a mental health hospital pharmacy and administered to patients at a mental health hospital in Victoria, Australia.

Tryparsamide (trade name) is sodium N-phenylglycineamide-p-arsonate, a compound containing 25% arsenic. Used in conjunction with malarial fever therapy to treat tertiary neuro-syphilis in patients diagnosed with General Paralysis of the Insane (GPI), having been originally developed for the treatment of human African trypanosomiasis, or African sleeping sickness. GPI was found to be caused by the spirochaete bacterium Treponema pallidum and later treated effectively with penicillin.

Physical Description

White paper leaflet with light blue printed text. Front describes form, indications and potential side-effects. Reverse describes clinical uses and administration for both neuro-syphilis and trypanosomiasis. May & Baker trademark and company details at bottom of page.

More Information